Does Amerigroup Cover Liraglutide (Saxenda)?

What Is Liraglutide (Saxenda) and Why Is It Prescribed?

Liraglutide 3 mg (Saxenda) is a glucagon-like peptide-1 (GLP-1) receptor agonist that reduces appetite and slows gastric emptying to support chronic weight management. The FDA approved Saxenda on June 27, 2014, specifically for adults with a BMI of 30 kg/m² or above, or a BMI of 27 kg/m² or above in the presence of at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. 1

Saxenda is distinct from liraglutide 1.8 mg (Victoza), which carries an FDA indication for type 2 diabetes management. Insurers treat these two doses differently on their formularies, and using the lower-dose diabetes product off-label for weight loss often results in automatic claim rejection.

The SCALE-Obesity and Prediabetes trial (N=3,731) showed that liraglutide 3.0 mg produced a mean 8.0% reduction in body weight at 56 weeks compared with 2.6% in the placebo group (P<0.001). 2 Roughly 63% of participants on liraglutide lost at least 5% of body weight. That clinical evidence base is what prescribers cite when submitting prior authorization (PA) requests to Amerigroup.

Saxenda is administered as a once-daily subcutaneous injection. The titration schedule begins at 0.6 mg per day and increases by 0.6 mg each week until reaching the full 3.0 mg maintenance dose in week five. 1 Patients who do not achieve at least 4% of their baseline body weight reduction by week 16 are generally advised to discontinue, as continued benefit is unlikely.

How Amerigroup Structures Its Drug Coverage

Amerigroup, a subsidiary of Elevance Health (formerly Anthem), operates Medicaid managed-care and Medicare Advantage plans across roughly 19 states. Each state contract produces a distinct formulary, so Amerigroup of Texas, Amerigroup of New Jersey, and Amerigroup of Tennessee may place Saxenda on completely different tiers or exclude it outright.

Federal Medicaid law does not require states to cover weight-loss medications. Under 42 C.F.R. § 440.390, agents used for anorexia, weight loss, or weight gain are classified as an optional benefit, meaning states can exclude them without violating federal requirements. 3 Several states that contract with Amerigroup have exercised that exclusion.

For Amerigroup Medicare Advantage members, the situation differs. Medicare Part D plans are permitted to cover anti-obesity medications starting in 2026 under the Treat and Reduce Obesity Act framework, but as of early 2025, most Part D formularies still exclude drugs with a primary indication of weight loss. Saxenda therefore appears on some Amerigroup Medicare Advantage specialty tiers only when prescribed for type 2 diabetes management at the 1.8 mg dose (Victoza), not at the 3.0 mg obesity dose.

Amerigroup commercial exchange plans (sold through ACA marketplaces) follow state benchmark-plan rules and may or may not include Saxenda. Members should download the current year's Evidence of Coverage document directly from Amerigroup's member portal or call the pharmacy benefits number on the back of their member ID card before assuming coverage exists.

The Centers for Medicare and Medicaid Services (CMS) requires managed-care organizations to publish their formularies and update them at least every 30 days. 4 Checking the Amerigroup formulary search tool at amerigroup.com with the most recent plan year selected is the fastest first step.

Prior Authorization Requirements for Saxenda Through Amerigroup

Prior authorization is nearly always required. Amerigroup's PA criteria for Saxenda typically include a documented BMI of 30 kg/m² or above (or 27 kg/m² or above with a qualifying comorbidity), evidence that a supervised diet and exercise program has been attempted for at least three to six months, and a clinical note confirming the absence of contraindications such as a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. 1

The prescribing clinician submits the PA request. Required documentation generally includes:

• Office visit notes confirming current height, weight, and calculated BMI
• Documentation of the comorbidity (A1c results, blood pressure readings, lipid panel)
• A treatment history showing prior lifestyle intervention attempts
• The Saxenda prescription itself, specifying the 3.0 mg dose

Amerigroup is required by CMS to process standard PA requests within 14 calendar days and expedited requests within 72 hours when a delay would seriously jeopardize the enrollee's health. 5 For Medicaid managed-care, federal rules at 42 C.F.R. § 438.210 require standard authorization decisions within 14 business days and expedited decisions within 72 hours. 6

If Amerigroup denies the PA, the denial letter must state the specific clinical reason. Save that letter. It drives the entire appeals strategy.

What to Do When Amerigroup Denies Saxenda Coverage

A denial is not the end of the road. The federal Medicaid appeals process allows members to file an internal appeal, then request a State Fair Hearing if the internal appeal fails. Medicare Advantage denials follow a separate five-level appeals ladder: Redetermination, Reconsideration by a Qualified Independent Contractor (QIC), ALJ Hearing, Medicare Appeals Council Review, and Federal District Court. 7

The most common grounds for a successful Saxenda appeal include:

Clinical necessity letter. An endocrinologist or obesity medicine specialist writing a detailed letter explaining why liraglutide is medically necessary for the specific patient, referencing published guidelines such as the 2022 American Association of Clinical Endocrinology (AACE) Obesity Clinical Practice Guidelines, strengthens the appeal substantially. The AACE guidelines state: "Anti-obesity medications are recommended as an adjunct to comprehensive lifestyle intervention for patients with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with complications." 8

Step therapy documentation. Some Amerigroup plans require that a member first try and fail another weight-loss agent (commonly orlistat or phentermine/topiramate) before Saxenda is authorized. Documenting that a prior agent was tried, produced inadequate results or intolerable side effects, and that Saxenda is therefore the next appropriate clinical step can satisfy step-therapy criteria.

Comorbidity severity. If the denial cited an insufficient BMI, additional documentation of comorbidity severity (for example, poorly controlled hypertension despite two antihypertensive agents, or an A1c above 8.0% despite metformin) may shift the clinical calculus enough to reverse the denial.

Amerigroup Medicaid members have the right to continued benefits during an appeal if the appeal is filed before the last day of authorized service. This protects access to medication while the appeal proceeds.

Saxenda Formulary Tier and Cost-Sharing Details

When Saxenda is covered, it typically appears on a specialty or non-preferred brand tier, which carries the highest cost-sharing. Medicaid members usually face minimal or zero copays for covered drugs under the plan's nominal cost-sharing rules. Medicare Advantage members may face a 25% to 33% coinsurance on specialty-tier drugs during the initial coverage phase.

The retail cash price for a 30-day supply of Saxenda (five 3 mL pens, each delivering 18 mg of liraglutide) runs approximately $1,300 to $1,500 without insurance, depending on the pharmacy. That price point makes coverage approval or manufacturer assistance programs financially material for most patients.

Novo Nordisk's Saxenda Patient Assistance Program provides the medication at no cost to patients who meet income thresholds (generally at or below 400% of the federal poverty level) and lack adequate insurance coverage. Applications are submitted at novonordisk-us.com or by calling 1-866-310-7549.

The NovoCare savings card, available to commercially insured patients only, can reduce out-of-pocket costs to as low as $25 per month for eligible members. It does not apply to Medicaid or Medicare Part D plans.

States Where Amerigroup Medicaid Has Historically Covered Saxenda

Coverage decisions are made at the state level, and they change. As of the most recent published formulary reviews, Amerigroup Medicaid plans in Georgia, Nevada, and Tennessee have listed Saxenda with prior authorization requirements. Plans in Florida and Texas have historically classified anti-obesity pharmacotherapy as a non-covered benefit, though formularies are updated annually.

The National Academy for State Health Policy (NASHP) tracks anti-obesity medication coverage across all state Medicaid programs. Their published coverage tracker shows that as of 2024, roughly 30 states cover at least one GLP-1 receptor agonist for obesity in their Medicaid programs, while the remaining states either exclude all anti-obesity agents or cover only those with a secondary diabetes indication. 9

Members should verify their specific state plan's current formulary rather than relying on historical data. Plan formularies for the current benefit year are accessible through the Amerigroup member portal, and a Pharmacy Benefits representative can confirm coverage in real time at the number on the member ID card.

How Liraglutide Compares to Other GLP-1 Agents in Medicaid Coverage

Saxenda is not the only GLP-1 option for obesity management, and Amerigroup plans that exclude Saxenda may cover an alternative. Semaglutide 2.4 mg (Wegovy) received FDA approval for chronic weight management on June 4, 2021. 10 In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced a mean 14.9% reduction in body weight at 68 weeks, compared with 2.4% in the placebo group (P<0.001). 11 That is nearly double the weight-loss efficacy seen with liraglutide 3.0 mg in SCALE-Obesity.

Tirzepatide (Zepbound), a dual GIP/GLP-1 receptor agonist, received FDA approval for obesity on November 8, 2023. 12 In SURMOUNT-1 (N=2,539), the 15 mg dose produced a mean 20.9% body weight reduction at 72 weeks versus 3.1% placebo (P<0.001). 13 Medicaid coverage for tirzepatide 2.5 to 15 mg (Zepbound) remains limited as of early 2025, but some Amerigroup plans have added it to formulary in states with progressive Medicaid obesity drug coverage policies.

If Saxenda is denied, ask the prescribing clinician to evaluate whether semaglutide (Wegovy) or tirzepatide (Zepbound) might be clinically appropriate and better positioned on your specific Amerigroup formulary.

The Clinical Case for Treating Obesity as a Disease

Insurance coverage decisions for Saxenda are sometimes contested because payers historically classified obesity treatment as elective or cosmetic. That framing is medically unsupported. The American Medical Association formally recognized obesity as a chronic disease in 2013, and the Obesity Medicine Association echoes that position. 14

The SCALE-Obesity trial demonstrated that liraglutide 3.0 mg reduced the rate of prediabetes progression to type 2 diabetes by 80% over 160 weeks compared with placebo. 15 Framing the PA request around diabetes prevention and cardiovascular risk reduction, rather than cosmetic weight loss, often improves approval rates. Documentation of an elevated fasting glucose (100 to 125 mg/dL), an elevated A1c (5.7% to 6.4%), or a 10-year ASCVD risk score above 7.5% provides the clinical hooks that PA reviewers are trained to approve.

The SCALE Diabetes trial (N=846) showed that liraglutide 3.0 mg produced a mean 6.0% body weight reduction at 56 weeks in patients with type 2 diabetes, compared with 2.0% in the placebo group (P<0.001), alongside improvements in A1c of 1.3 percentage points. 16 Including that data in a PA appeal letter for a patient with existing type 2 diabetes makes the medical necessity argument substantially stronger.

Practical Steps to Maximize Approval Odds

Start with a specific visit note. The prescribing clinician should document exact height, weight, BMI, relevant labs, prior weight-loss interventions, and the clinical rationale for Saxenda specifically (not just any anti-obesity medication). Vague notes produce PA denials.

Confirm the correct NDC. Amerigroup PAs are tied to specific National Drug Codes. Saxenda's NDCs differ from Victoza's. A mismatch causes automatic rejection even when the clinical criteria are met.

Submit the PA before writing the prescription. Patients who fill the prescription expecting retroactive reimbursement almost always pay out of pocket. The PA must be approved first.

Track the timeline. Standard Medicaid PA decisions within 14 business days. If Amerigroup misses that deadline without notifying the member, that procedural lapse may itself constitute grounds for a complaint to the state Medicaid agency, which often accelerates resolution.

Use the prescriber's office PA coordinator. Most practices that prescribe Saxenda regularly have staff experienced with payer-specific PA forms. Their familiarity with Amerigroup's preferred clinical terminology can materially shorten the approval timeline.

Request a peer-to-peer review. If the PA is denied, the prescribing physician can request a real-time phone conversation with Amerigroup's medical director handling the case. Studies of commercial payer peer-to-peer outcomes suggest that roughly 50% of initially denied authorizations are reversed after physician-to-physician discussion. 17